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The prolactin receptor (PRLR) is emerging as a therapeutic target in oncology. Knowledge-
based drug design led to the development of a pure PRLR antagonist (Del1-9-G129R-
hPRL) that was recently shown to prevent PRL-induced mouse prostate tumorogenesis. In
humans, the ﬁrst gain-of-function mutation of the PRLR (PRLRI146L) was recently identiﬁed
in breast tumor patients. At the molecular level, the actual mechanism of action of these
two novel players in the PRL system remains elusive. In this study, we addressed whether
constitutive PRLR activation (PRLRI146L) or PRLR blockade (antagonist) involved alter-
ation of receptor oligomerization and/or of inter-chain distances compared to unstimulated
and PRL-stimulated PRLR. Using a combination of various biochemical and spectroscopic
approaches (co-IP, blue native electrophoresis, BRET1), we demonstrated that preformed
PRLR homodimers are altered neither by PRL- or I146L-induced receptor triggering, nor by
antagonist-mediated blockade.These ﬁndings were conﬁrmed using a novel time-resolved
ﬂuorescence resonance energy transfer (TR-FRET) technology that allows monitoring dis-
tance changes between cell surface tagged receptors.This technology revealed that PRLR
blockade or activation did not involve detectable distance changes between extracellu-
lar domains of receptor chains within the dimer. This study merges with our previous
structural investigations suggesting that the mechanism of PRLR activation solely involves
intermolecular contact adaptations leading to subtle intramolecular rearrangements.
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INTRODUCTION
The prolactin receptor (PRLR) is emerging as a novel therapeu-
tic target in human diseases (Gofﬁn et al., 2006; Rouet et al.,
2010). The main indications include prostate and breast cancer
in which locally produced prolactin (PRL) probably more than
the circulating hormone has been proposed to promote tumor
growth (Clevenger et al., 2003; Li et al., 2004;Dagvadorj et al., 2007;
McHale et al., 2008). In addition, we recently identiﬁed the ﬁrst
gain-of-function mutation of this receptor (so-called PRLRI146L)
in patients presenting with breast tumors, further supporting the
involvement of PRLR signaling in human tumorogenesis (Bogo-
rad et al., 2008). Current anti-PRL drugs are dopamine agonists,
which efﬁciently target pituitary PRL production (Molitch, 2005).
However, such compounds are per se inappropriate in targeting
extrapituitary-produced PRL (whose expression is believed to be
dopamine-independent) or PRLRI146L (whose constitutive activ-
ity is PRL-independent). Strategies targeting the receptor itself
are thus necessary. Engineered ligands exhibiting antagonistic
properties are currently viewed as a promising approach (Tallet
et al., 2008). Accordingly, our group has recently developed pure
competitive antagonists, the prototype of which was named Del1-
9-G129R-hPRL (Bernichtein et al., 2003b). The latter efﬁciently
down-regulates PRLR signaling triggered by autocrine PRL (Dag-
vadorj et al., 2007; Rouet et al., 2010) as well as by PRLRI146L
(Bogorad et al., 2008). The development of novel therapeutic com-
pounds, either engineered from the PRL core or chemically syn-
thesized, requires a better understanding of the molecular/atomic
changes underlying PRLR activation and pharmacological block-
ade. Within the past few years, our group has provided structural
insight into the PRL family by determining three-dimensional
structures of free agonist/antagonist ligands (PRLWT, Del1-9-
G129R-hPRL) and PRL-receptor complexes (Teilum et al., 2005;
Jomain et al., 2007; Broutin et al., 2010;VanAgthoven et al., 2010).
Although these structures provided very helpful atomic level char-
acterization of protein–protein interaction sites, the comparison
of free and bound structures allowed only limited speculation
on the dynamic properties of membrane-anchored receptors,
especially regarding the recently discovered PRLRI146L variant.
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The PRLR is a pioneering member of the class I hematopoietic
cytokine receptor family (Kelly et al., 1991). This non-tyrosine
kinase, single-pass transmembrane receptor family comprises
nearly 50 members that exhibit wide heterogeneity regarding the
stoichiometry of receptor chain assembly (Boulay et al., 2003).
Together with the receptors for growth hormone (GHR), lep-
tin (OBR), erythropoietin (EPOR), thrombopoietin (TPOR), and
granulocyte colony stimulating factor (G-CSFR), the PRLRdeﬁnes
a subclass of cytokine receptors adopting the simplest model of
receptor assembly, since functional receptors involve only a sin-
gle type of chain which is assumed to homodimerize. Mutational
and structural studies of PRL have identiﬁed two binding sites,
each able to interact with one receptor chain (Gofﬁn et al., 1996b;
Broutin et al., 2010). The functional importance of both sites was
demonstrated by the fact that mutations of hot spot residues at
site 1 prevented receptor binding in cell-based assays (Gofﬁn et al.,
1992; Kinet et al., 1996). On the contrary, steric mutations intro-
duced within PRL binding site 2 did not prevent receptor binding
but resulted in competitive receptor antagonists unable to trigger
signaling (Bernichtein et al., 2003b; Jomain et al., 2007). Sur-
face plasmon resonance (SPR) using immobilized and oriented
PRLR extracellular domain (ECD) was used to monitor sequen-
tial interaction of two ECDs with PRL binding site 1 then 2.
These studies revealed that the afﬁnity of site 1 for the PRLR-ECD
was in the nanomolar range (which is similar to the afﬁnity for
membrane-anchored PRLR), while that of site 2 was much lower
(micromolar). While PRLR antagonists displayed unchanged site
1 afﬁnity, no interaction involving site 2 was detectable (Jomain
et al., 2007). Although these ﬁndings suggested that the antago-
nistic properties of site 2 mutants resulted from their inability to
interact with a second receptor moiety – which was in good agree-
ment with the original model of sequential receptor dimerization
(Fuh et al., 1993; Gofﬁn et al., 1994) – extrapolation of SPR data
to membrane-anchored receptors must remain very cautious.
Indeed, recent reports have suggested that the PRLR, as
many cytokine receptors (if not all), is present in a pre-
assembled form at the plasma membrane. Using BRET1 (ﬂuo-
rescent/bioluminescent tags added to the C-terminus of recep-
tors) and co-immunoprecipitation (co-IP) approaches, Qazi et al.
(2006) suggested that the membrane PRLR was constitutively
homodimerized (or heterodimerized when long and short iso-
forms were co-expressed in the same cell). These ﬁndings were in
agreement with another report involving co-IP, which also con-
cluded to the existence of ligand-independent homodimers of
human PRLR isoforms, and proposed a signiﬁcant role for the
transmembrane domain in stabilizing the dimer (Gadd and Cle-
venger, 2006). These two reports further agreed on the fact that
any qualitative or quantitative alteration of PRLR dimerization
induced by the ligand was beyond the detection limits of the tech-
niques used. Otherwise, BRET2 technology applied to various C-
terminal tagged PRLR isoforms revealed an effect of ligand bind-
ing on ﬂuorescence signals, that discriminated receptor agonists
(hPRLWT and S179D-hPRL) from a partial agonist/antagonist
(G129R-hPRL; Tan et al., 2005). Although at that time the authors
could not speculate whether these ﬁndings reﬂected the ability of
agonists to recruit monomers into dimers or to induce confor-
mational changes in the cytoplasmic tails of pre-existing dimers,
the subsequent demonstration that non-stimulated PRLR exists as
preformed dimers (Tan et al., 2005; Qazi et al., 2006) clearly argues
for the second hypothesis.
These ﬁndings have pushed one step forward several unan-
swered questions regarding the actual activation mechanism of
this receptor. These include: do agonists trigger receptor sig-
naling by inducing important conformational changes of the
ECDs, that next reverberate onto the cytoplasmic domain? Does
PRLRI146L intrinsically adopt a conformation similar to that of
PRL-activated PRLRWT? Does Del1-9-G129R-hPRL prevent these
conformational changes or, even disrupt the preformed dimer?
Does activation of the latter involve signiﬁcant distance changes
between the two ECDs, or only subtle intramolecular conforma-
tional changes within the ECD(s)? Are the interacting regions of
PRL and PRLR the best targets to design inhibitors, or could the
understanding of PRLR activation identify alternative/more efﬁ-
cient regions for future drug design? Although resonance energy
transfer technologies (BRET, FRET) are currently the most pow-
erful experimental approaches to address such issues, several
drawbacks are encountered using these approaches. First, the low
signal-to-noise ratio due to high background and/or to signal
generated by ﬂuorescent/bioluminescent proteins present in the
intracellular compartment can hamper the detection of speciﬁc
signal induced by extracellular ligands. This is especially true for
the PRLR which mainly resides inside the cell. Another impor-
tant limit of classical FRET/BRET involves the interpretation of
the results. Indeed, the absence of signal does not necessarily
reﬂect the absence of physical protein–protein interactions, since
unsuitable relative orientation of ﬂuorophore dipoles can prevent
energy transfer between interacting proteins (Pﬂeger and Eidne,
2006; Vogel et al., 2006). Conversely, as stated above, it is virtually
impossible to translate changes of signal intensities (e.g., induced
by ligands) into changes of distance, of orientation or both.
To address this issue, we have used the newly developed
time-resolved ﬂuorescence resonance energy transfer (TR-FRET)
technology, which circumvents such drawbacks (Degorce et al.,
2009). It involves the use of terbium cryptate (Lumi4 Tb) as a
donor, and red or green ﬂuorophores as acceptors (see Experi-
mental Procedures). Such ﬂuorophore combinations allow much
higher signal-to-noise ratio compared to classical FRET. A second
advantage of TR-FRET is that signals only depend on the dis-
tances between interacting proteins, as energy transfer efﬁciency is
mostly independent of the relative dipole orientation of the donor
and acceptor molecules. Third, when ﬂuorophores are speciﬁcally
targeted to the plasma membrane thanks to the use of receptor-
tag chimera labeled with non-permeant synthetic substrates, one
can selectively analyze the proximity between cell surface recep-
tors without being hampered by the pool of intracellular tagged
receptors. Finally, as tags are linked to the N-terminal end of the
receptors,TR-FRET is suitable tomonitor distance changes (move-
ments) between ECDs. This feature was particularly appropriate
for our purpose since: (i) I146L mutation is located within the
S2 subdomain of the ECD (Bogorad et al., 2008), and (ii) the
pure antagonistic properties of Del1-9-G129R-hPRL are obviously
mediated though the interaction of the latter with the PRLR-ECD.
In the present work,we thus applied TR-FRET technology to study
various activation states of the PRLR,which involved comparisons
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between PRLRWT and PRLRI146L, either unbound or bound to
receptor agonist (PRL) or pure antagonist (Del1-9-G129R-hPRL).
As this was the ﬁrst time TR-FRET technology was applied to a
member of the cytokine family, it was combined to more classical
approaches (BRET, co-IP, native electrophoresis) in order to allow
direct comparison with previously published data in the ﬁeld.
MATERIALS AND METHODS
HORMONES AND ANTIBODIES
Recombinant, chromatography puriﬁed hPRL and Del1-9-
G129R-hPRL antagonist were prepared and characterized as pre-
viously described (Bernichtein et al., 2003b). Purity of hormone
preparations used in this study was >95% as judged from SDS-
PAGE analysis. For ligand binding FRET assays, both recombinant
hormones were labeled with Red ﬂuorophore using the d2 labeling
kit (Ref. 62D2DPEA, Cisbio Bioassays, Codolet, France). Various
batches of labeled protein were obtained with ﬁnal molar ratio of
0.8–3. The bioactivity of labeled proteins was assessed using the
lactogenic hormone response element (LHRE)-luciferase reporter
gene assay previously described (Bernichtein et al., 2003a). Labeled
prolactin exhibited bioactivity similar to unlabeled hormone,
although a slight shift to the right of dose–response curves was
observed for the batches carrying the highest level of ﬂuorophores
(data not shown).
Antibodies used for (co-)IP and immunoblots were the follow-
ing: anti-Stat5a/b (C-17, rabbit polyclonal, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) used at 0.4μg/mL for IP and
0.02μg/mL in blots; anti-HA (Roche, Basel, Switzerland, clone
12CA5), used at 0.8μg/mL for IP and 0.08μg/mL in blots,
anti-phosphorylated Stat5a/b (AX1,mousemonoclonal,Advantex
BioReagents, Conroe, TX, USA), used at 1:10,000 in blots; anti-
human PRLR (Invitrogen-Zymed, 1A2B1, Carlsbad, CA, USA),
used at 1:1,000 in blots.
GENERATION OF hPRLRWT AND hPRLRI146L TAGGED CONSTRUCTS
Fluorescence resonance energy transfer constructs were generated
by introducing the coding sequence of the hPRLR long isoform
(cDNA originally in pcDNA3.1 vector and containing the rat sig-
nal peptide, rSP; Lochnan et al., 1995) into pRK5-HA-ST plasmid,
containing the two tags of interest (HA and ST). Brieﬂy, an MluI
site was inserted by site-directed mutagenesis (QuikChange Muta-
genesis II kit, Stratagene, La Jolla, CA, USA) between the signal
peptide and the ATG initiation codon of pRK5-rSP-hPRLRWT
plasmid. Then, the PRLR coding sequence excised using SpeI and
MluI enzymes was sub-cloned into linearized pRK5-mGluR5PS-
HA-ST vector, produced by SpeI–MluI restriction of previously
described pRK5-mGluR5PS-HA-ST-GB1R plasmid (Maurel et al.,
2008). In the ﬁnal pRK5-HA-ST-hPRLR vector, a linker of two
amino acids connects the Snap tag to the N-terminus of the
receptor. The HA-ST-hPRLRI146L encoding vector was generated
by site-directed mutagenesis of pRK5-HA-ST-hPRLRWT using
primers earlier reported (Bogorad et al., 2008). After transforma-
tion, Escherichia coli JM109 colonies were analyzed for their DNA
content; recombinant plasmids were sequenced to assess sequence
integrity and the presence of expected tags. FRET vectors encod-
ing mGluR2 and CD4 receptors were described in a previous study
(Maurel et al., 2008).
BRET constructs were generated by linking Rluc and YFP
encoding sequence in 3′ of PRLR coding sequence contained in
pcDNA3.1-hPRLRWT vector. Brieﬂy, an EcoRV restriction site was
substituted for the hPRLR stop codon by site-directed mutage-
nesis (generating pcDNA3.1-hPRLR(EcoRV)). Similarly, an EcoRV
restriction site was introduced in 5′ of Rluc coding sequence con-
tained in pcDNA3-CMV-hRluc plasmid (kindly provided by Dr.
R. Jokers), generating pcDNA3-CMV-(EcoRV)hRluc. The Rluc frag-
ment was extracted from pcDNA3-CMV-(EcoRV)hRluc by EcoRV-
Not I digestion and sub-cloned intopcDNA3.1-hPRLR(EcoRV) plas-
mid linearized by EcoRV+Not I digestion. In the ﬁnal construct
(pcDNA3.1-hPRLRWT-Rluc), a sequence encoding 12 amino acids
(DICRWDPPARAT) links PRLR and Rluc coding sequences. The
YFP DNA fragment was obtained by EcoRV-Not I restriction of
pcDNA-CMV-topaze (kindly provided by Dr. R. Jokers), then sub-
cloned into EcoRV+Not I linearized pcDNA3.1-hPRLR(EcoRV)
plasmid. In the ﬁnal construct (pcDNA3.1-hPRLRWT-YFP), a
sequence encoding 16 amino acids (DIKLAVPRARDPPVAT) links
PRLR and YFP coding sequences. Both Rluc- and YFP-hPRLRWT
encoding vectors were site-directed mutated to generate cog-
nate hPRLRI146L vectors. All plasmids were veriﬁed by restriction
enzyme mapping and sequencing in both directions to ensure that
fusion protein cDNA were in frame and to discard any unexpected
mutation.
ROUTINE CELL CULTURE
HEK 293 and COS-7 cells were routinely cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Invitrogen), containing 10%
FBS, 50U/mL penicillin, 50μg/mL streptomycin (Invitrogen,
Grand Island, NY, USA), and 2mM Glutamine, at 5% CO2 and
37˚C.HL-5, a stableHEK 293 cell line that integrated in its genome
the LHRE-luciferase reported gene and the hPRLRWT cDNA, was
described in previous publications (Bernichtein et al., 2003a,b).
They were cultured in the same media as described above, with
the addition of 500μg/mL Geneticin.
Ba/F3 cells are a murine pro-B cell line that is dependent on
Interleukin-3 (IL-3) for growth. They were routinely maintained
in RPMI 1640 medium supplemented with 10% heat-inactivated
FBS, 2mM glutamine, 50U/mL penicillin, 50μg/mL strepto-
mycin, and 10% WEHI cell supernatant as source of IL-3 (Ber-
nichtein et al., 2003a). Ba/F-LP is a selected population of Ba/F3
cells stably expressing the hPRLRWT (Bernichtein et al., 2003a);
this particular cell line was cultured in the presence of 10 ng/mL
hPRL instead of IL-3 (no addition of WEHI supernatant) and of
500μg/mL Geneticin.
TRANSIENT AND STABLE TRANSFECTION OF HEK 293 AND COS-7 CELLS
For transient transfections of untagged, FRET, or BRET PRLR
constructs, we used lipofectamine 2,000 reagent (Invitrogen,
Grand Island, NY, USA) and we strictly followed the manufac-
turer’s instructions. As pRK5 FRET vectors encoding PRLRWT or
PRLRI146L contain no eukaryote antibiotic resistance, the genera-
tion of stable HEK 293 clones was performed by co-transfecting
these plasmids together with empty pcDNA3.1 plasmid (contain-
ing geneticin resistance). We used Fugen reagent (Roche) and we
followed manufacturer’s instructions with respect to DNA quan-
tity ratio (10:1). After 48 h, Geneticin (500μg/mL) was added for
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selection. After 2–3weeks, clones were individually expanded and
characterized for PRLR expression and PRL-responsiveness using
immunoblot (see below). Two clones were selected for each recep-
tor according to expression levels of the PRLR as determined by
direct ﬂuorescence at 620 nm (see below). These FRET clones were
named PRLRhigh or PRLRlow (for both PRLRWT and PRLRI146L).
WESTERN BLOT AND CO-IMMUNOPRECIPITATION ANALYSES
HEK 293 cells (2× 106) were plated in 10 cm Petri dishes and
transfected using the plasmids of interest, alone or in combination.
After 48 h, cells were washed twice in cold PBS then scratched in
1mL PBS containing protease inhibitor cocktail (Complete Mini,
Roche). After 5min centrifugation at 800 g, cell pellets were resus-
pended in lysis buffer (50mM Tris–HCl pH 7.5, 150mM NaCl,
1% Nonidet P40, 0.5% Deoxycholic acid, 0.1% SDS) in the pres-
ence of 2mM Na-orthovanadate and protease inhibitor cocktail
(30min, 4˚C). Lysates were centrifuged 13,000 g (4˚C) and super-
natants were collected before protein content was determined by
Bradford assay.
Analysis of PRLR expression was performed by immunoblot.
Cell lysates were resolved on 7.5% SDS-PAGE followed by transfer
onto nitrocellulose membrane (mini-protean, Biorad, Hercules,
CA, USA). After blocking (TBS 5% milk/0.1% Tween 20), mem-
branes were incubated overnight with the appropriate primary
antibody (diluted in TBS-T 3% BSA) at 4˚C. Secondary anti-
mouse (GE Healthcare) or anti-rabbit (Cell Signaling, Danvers,
MA, USA) antibodies conjugated to horseradish peroxidase were
incubated for 1 h at RT before detection of antigen-antibody com-
plexes by enhanced chemiluminescence (GE Healthcare, Orsay,
France).
Co-IP of untagged and HA-tagged PRLRs was performed
by incubating cell lysates with anti-HA antibody (0.8μg/mL)
overnight at 4˚C on rotary shaker. Protein A-Sepharose beads
(GE Healthcare) were added for one additional hour (4˚C under
rotation). Immune complexes bound to the beads were washed
twice in lysis buffer before resuspension in 20μL loading buffer
containing 2-mercaptoethanol. After heating (90˚C, 5min), sam-
ples were processed by SDS-PAGE and immunoblot as described
above. Densitometric analyses were performed using ImageJ soft-
ware. Data from two experiments were averaged. The [untagged
PRLR/HA-PRLR] densitometric ratios in total lysates (bottom
panels in Figure 2) were close to 1, indicating similar level
of expression of both constructs. For each stimulation condi-
tion, this value was used to normalize band intensities calculated
for co-IP, as follows: [untagged PRLR/HA-PRLR]co-IP/[untagged
PRLR/HA-PRLR]total lysates.
BLUE NATIVE PAGE
Cells were stimulated at 37˚C with hPRL (1μg/mL) and harvested
by scraping on ice. Then, they were collected by brief centrifu-
gation (1,000 g, 5min) and strongly homogenized using a tight
ﬁtting glass homogenizer in a hypotonic lysis buffer (10mM Tris,
pH7.5,0.2M sucrose, 2mMEDTA,50mMNaﬂuoride,30mMNa
pyrophosphate,andprotease inhibitor cocktail). Thehomogenates
were then centrifuged at 5,000 g for 10min to eliminate cell debris
and nuclei. The supernatants were kept on ice while the pellet
was resuspended, homogenized, and centrifuged again. Both step
supernatants were combined then centrifuged at 120,000 g for 1 h
at 4˚C, and the ﬁnal pellet containing crude membranes was kept
frozen at −80˚C until use.
To solubilize membrane proteins and complexes, the mem-
brane pellet was vigorously resuspended in extraction buffer using
a pipette (50mM Bis–Tris–HCl pH 7.2, 50mM NaCl, 10% w/v
glycerol, and 0.001% Ponceau S,Native PAGE sample buffer, Invit-
rogen). Dodecyl-β-d-maltoside (DDM, Acros Organics) was then
added to the membranes at a ﬁnal concentration of 0.4% (or
other concentration when indicated). After incubation on ice for
30min (vortexing every 5min), insoluble material was pelleted
at 120,000 g for 30min. Coomassie G250 was then added to the
samples (0.5% ﬁnal) for 5min on ice before loading on blue native
gels.
Blue Native PAGE (BN-PAGE) were performed according to
a modiﬁed version of the protocol by Schagger and von Jagow
(1991). A precast 4–16% polyacrylamide gradient gel was used to
perform native (non-denaturing) electrophoresis (Native PAGE
4–16% Bis–Tris gel, Invitrogen). The migration was performed
in a XCell SureLock Mini-Cell cuve (Invitrogen). The cathode
buffer (50mM Bis–Tris–HCl pH 6.8, 50mM Tricine) containing
0.02% Coomassie G250 and the anode buffer (50mM Bis–Tris–
HCl, 50mM Tricine pH 6.8) were chilled to 4˚C before sample
loading. Electrophoresis started at 4mA (4˚C). After 90min, the
cathode buffer was replaced by the same buffer containing 0.005%
of the dye, and the electrophoresis was continued at 8mA with
voltage set at 120V. After the dye front had run off the gel, the
gel was washed with dissociating solution (0.1% SDS, 50mM
DTT) for 10min at room temperature. Then, transfer onto PVDF
membrane (Millipore) was performed as described above.
TR-FRET ANALYSES
Clones used for FRET studies (called PRLRhigh and PRLRlow) or
transient transfected cellswere plated in culturedmediumat a den-
sity of 100,000 cells/well using 96 well white plate pre-coated with
polyornithin (50 μL of 0.1mg/mL polyornithin added per well for
>1 h at 37˚C). After 16 h (allowing cell adhesion), ST-PRLRs were
labeled by SNAP-Lumi4 Tb (100 nM) in combination or not (con-
trol wells) with SNAP-acceptor [Red (500 nM) or Green (100 nM);
Cisbio Bioassays, Codolet, France], in culture medium for 1 h at
37˚C.Wellswerewashed twicewithTris-Krebs buffer (20mMTris–
HCl pH 7.4, 188mM NaCl, 1.2mM KH2PO4, 1.2mM MgSO4,
4.7mM KCl, 1.8mM CaCl2) and wells ﬁlled with 100μL Tris-
Krebs buffer. Plate reading was performed using a Mithras LB 940
reader (Berthold) upgradedwithTRmodule: excitation at 340 nm,
emission at 620 nm for Lumi4Tb detection, 665 nm for Red accep-
tor, and 520 nm for Green acceptor. After stimulation by hPRL or
Del1-9-G129R-hPRL antagonist, measurements were repeated for
the indicated time.
Normalized FRET was calculated as follows:
Normalized FRET =
[
Speciﬁc FRET signal
Speciﬁc PRLR labelling
]
=
[(
SFRET cell line665nm
)
Donor+Acceptor −
(
SFRET cell line665nm
)
Donor(
SFRET cell line620nm
)
Donor −
(
SHEK 293620nm
)
Donor
]
Frontiers in Endocrinology | Cellular Endocrinology September 2011 | Volume 2 | Article 29 | 4
Tallet et al. TR-FRET applied to the prolactin receptor
Signal was represented as ΔR signal= f(ligand concentration)
or f(time) after data reduction with following calculation method:
ΔR =
([
S665nm
S620nm
]
Donor+Acceptor
−
[
S665nm
S620nm
]
Donor
)
∗ 104
Results presented are representative of at least three inde-
pendent experiments performed in triplicate. Representation and
statistical analysis (t -test) were performed using GraphPad Prism
software.
BRET ANALYSES
HEK 293 cells were plated at a density of 50,000 cell/well
using white (luminescence and BRET measurements) or black
(total YFP ﬂuorescence) 96 well plates, pre-coated with polyor-
nithin (see above). After 16 h, transfection was performed with
DNA/lipofectamine 2,000 mix as recommended by the manufac-
turer, using DNA amount as indicated in the Legends. Medium
was replaced 6–8 h post-transfection. After 36 additional hours
(to ensure proper PRLR expression), cells were stimulated for
15min by adding hPRL or Del1-9-G129R-hPRL antagonist, in
the presence or in the absence of 0.015% of saponin, before BRET
measurement. BRET signalswere detected after additionof coelen-
terazine h (5μMﬁnal concentration) in eachwell (white plate) and
followed in time. Signal detection was performed using Mithras
LB 940 reader (Berthold, Thoiry, France). Bioluminescence emis-
sion of Renilla luciferase was measured at 485 nm, ﬂuorescence
emission of YFP at 530 nm. The relative expression level of PRLR–
YFP fusion proteins was evaluated by measuring YFP ﬂuorescence
emitted at 530 nm after 485 nm lamp excitation using black plates.
Data reduction was done with following calculation method
(Boute et al., 2001):
BRET signal
=
([
Em530nm
Em485nm
]
Donor + Acceptor
−
[
Em530nm
Em485nm
]
Donor
)
∗ 103
Results are representative of at least three independent experi-
ments performed in triplicate and plotted using GraphPad Prism
software to determine Bmax for each stimulation condition in each
independent experiment. Data are represented as averaged per-
centages of Bmax or of basal BRET signal (i.e., non-stimulated
condition). Statistical analysis was performed by using a two-
tailed Student’s t -test when two groups were compared, which
was conﬁrmed by one-way ANOVA for comparison of the three
stimulation conditions.
TR-FRET BINDING ASSAYS
FRET stable cell lines (PRLRhigh) were plated in cultured medium
at a density 100,000 cells/well in 96 well white plates pre-coated
with polyornithin. After 16 h, ST-PRLRs were labeled by SNAP-
Lumi4 Tb (100 nM) in cultured medium for 1 h at 37˚C. Wells
werewashed twicewithTris-Krebs buffer, then theywereﬁlledwith
50μL Tris-Krebs buffer supplemented with 0.1% BSA. After addi-
tion of various concentrations of hPRL-Red or Del1-9-G129R-
hPRL-Red (added as 50μL of [2×] concentrated protein diluted
in Tris-Krebs buffer, 0.1% BSA), FRET signals were measured
over 24 h. Plate reading was performed using Mithras LB 940
reader (Berthold) upgradedwithTRmodule: excitation at 340 nm,
emission at 620 nm for Lumi4Tb detection, or 665 nm for Red
acceptor.
Representations correspond to 3 h of ligand stimulation at
room temperature. Control wells were done with excess of
non-labeled hPRL or Del1-9-G129R-hPRL antagonist.
Results are representative of at least three independent exper-
iments performed in triplicate. The binding afﬁnities of hPRL or
antagonist were calculated by curve ﬁtting with saturation bind-
ing equation (one site – speciﬁc binding) using GraphPad Prism
software.
RESULTS
FUNCTIONAL CHARACTERIZATION OF TR-FRET AND BRET PRLR
CONSTRUCTS
The various fusion constructs used for this study (Figure 1A) were
generated from the coding sequence of long human (h) PRLR iso-
form, either PRLRWT or PRLRI146L (Bogorad et al., 2008). For
constructs to be used in TR-FRET, we inserted two tandem N-
terminal tags: HA (hemagglutinin) and SNAP tag (ST; Tag Lite
technology, CisBio Bioassays). For BRET studies, Yellow Fluo-
rescent Protein (YFP), or Renilla luciferase (Rluc) were added
at the C-terminus of the PRLRs. Expression and activity of all
PRLR variants were assessed using transiently transfected HEK
FIGURE 1 | Functional validation of tagged PRLR constructs. (A)
Schematic representation of different constructs used in this study. From
left to right: tagged constructs used for TR-FRET experiments (insertion of
HA and ST at PRLR N-terminus), untagged receptors and fusion receptors
used for BRET experiments (insertion of Rluc or YFP at PRLR C-terminus).
PRLRWT is represented in gray and PRLRI146L in black. Symbols: HA,
hemagglutinin; ST, SNAP tag; Rluc, Renilla luciferase; YFP, yellow
ﬂuorescent protein. Note that the sizes of PRLR and tags as represented
are not proportional to actual molecular masses. (B) PRLR expression in
transient transfection (HEK 293 cells) was assessed by immunoblotting
using a αPRLR mAb (non-transfected cells are shown on the right lane).
Based on the electrophoretic mobility of untagged PRLR (∼90 kDa), the
apparent size of tagged receptors was in agreement with the theoretical
size of the various tags (21 kDa for HA–ST, 36 kDa for Rluc, and 27 kDa for
YFP). The PRL-responsiveness of all receptors (hPRL 1μg/mL added for
15min at 37˚C) was assessed by monitoring tyrosine phosphorylation of
immunoprecipitated (IP) Stat5 using a speciﬁc phospho-Stat5 mAb.
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293 cells. As shown on Figure 1B, all expressed proteins exhibited
the expected electrophoretic mobility as determined by αPRLR
immunoblot. Whatever the tagged isoform considered, no dif-
ference in expression level was noticed between WT and I146L
receptors.All constructs retained the ability to induce STAT5phos-
phorylation, indicating that the various tags did not signiﬁcantly
alter the biological activity of the PRLR. For all but Rluc con-
structs, bioactivity was further conﬁrmed using the classical PRL-
responsive LHRE-Luciferase reporter plasmid assay previously
described (Bernichtein et al., 2003a; data not shown). As earlier
reported, the basal activity of hPRLRI146L constructs (including
the untagged one) was hardly detectable using this readout in
transient transfection (Gofﬁn et al., 2010).
USE OF BIOCHEMICAL APPROACHES TO CHARACTERIZE BASAL AND
LIGAND-INDUCED HOMO- AND HETERO-DIMERIZATION OF hPRLRWT
AND hPRLRI146L
Co-IPwas used (i) to address the ability of unstimulated hPRLRWT
and hPRLRI146L to form homo and/or heterodimers, and (ii) to
test the effect of receptor triggering (using hPRL) or receptor
blockade (using Del1-9-G129R-hPRL) on this property. For this
purpose, we co-transfected plasmids encoding HA-ST-tagged or
untagged PRLRs (WT and I146L, alone or together) in HEK 293
cells. Then receptor complexes were immunoprecipitated using
anti-HA mAb and ﬁnally revealed using αPRLR immunoblotting.
The speciﬁcity of HA mAb in IP experiments was demonstrated
by its inability to pull-down untagged PRLR (data not shown).
Immunoblotting of total cell lysates served as control of equivalent
PRLR expression.
As shown on Figure 2A, IP of HA-ST-hPRLRWT pulled down
untagged hPRLRWT in the absence of stimulation, conﬁrming
that this experimental procedure was appropriate to identify pre-
formed receptor complexes earlier proposed to be homodimers
(Gadd and Clevenger, 2006). As far as can be deduced using
this semi-quantitative approach, stimulation by PRL, by a pure
antagonist or both, reproducibly failed to consistently modify
the amount of co-immunoprecipitated untagged PRLR. These
results were conﬁrmed by densitometric analysis performed as
described in Section “Materials and Methods,” with co-IP/total
lysate PRLRWT ratios equal to 0.74, 0.71, and 0.70 in basal,
+PRL, and +antagonist conditions, respectively. The same exper-
iments were repeated using PRLRI146L constructs (Figure 2B) and
achieved very similar results (co-IP/total lysate ratios equal to
0.81, 0.77, and 0.78 in basal, +PRL, and +antagonist conditions,
respectively). As PRLRI146L mutation was so far identiﬁed only
in heterozygous patients (Bogorad et al., 2008), it was relevant to
investigate its potential interaction with PRLRWT. This was per-
formed by immunoprecipitating the potential heterocomplexes
via HA-tagged PRLRWT (Figure 2C) or HA-tagged PRLRI146L
(Figure 2D). In both conﬁgurations, co-IP of the untagged recep-
tor was observed, which appeared qualitatively similar to what
was observed in homodimerization experiments (Figures 2A,B).
Although the antagonist seemed to result in a slight decrease
of PRLRI146L co-IP by HA-PRLRWT (Figure 2C), this was not
conﬁrmed by the reverse experiment (Figure 2D).
Taken together, these ﬁndings indicate that (i) I146L mutation
does not induce consistently detectable modiﬁcation of receptor
stoichiometry, (ii) PRLRI146L can heterodimerize with PRLRWT,
(iii) the antagonistic properties of Del1-9-G129R-hPRL are not
mediated by a disruption of preformedPRLRhomo/heterodimers,
whatever the receptor involved.
In order to conﬁrm the existence of receptor complexes in
native conditions, we used blue native polyacrylamide gel elec-
trophoresis (BN-PAGE) followed byαPRLR immunobloting using
a monoclonal antibody targeting the ECD of the human receptor.
In control conditions, the migration proﬁle of PRLRWT expressed
in so-called HL-5 clone (Bernichtein et al., 2003a) exhibited two
major bands,which does not exclude that other (bigger) complexes
not detected by this approach (e.g., due to masked epitopes) may
also exist (Figure 3A). The proﬁle of PRLRI146L was very similar
to that of PRLRWT, therefore we focused on the latter to investi-
gate the nature of these two bands. Solubilized membrane extracts
were then treated using various denaturing conditions (2M urea,
50mM DTT, up to 0.8% DDM, 60˚C heating), among which only
heating modiﬁed the proﬁle that now appeared as a single band
(the faster migrating one), which was assigned to the monomeric
FIGURE 2 | PRLRWT and PRLRI146L form homo and heterodimers. HEK 293
cells were co-transfected using various combinations of plasmids encoding
HA-tagged (*) or untagged (**) PRLR (WT and I146L), as indicated in (A–D).
Stimulation was performed using 500 ng/mL hPRL or 20μg/mL
Del1-9-G129R-hPRL, alone or in combination (15min, 37˚C). Co-IPs of
receptor complexes from 1mg cell lysates were performed using anti-HA
antibody. The presence of tagged and untagged PRLR in immune complexes
(black arrowheads) was determined by αhPRLR immublotting (IB) after 7.5%
SDS-PAGE. These experiments show that PRLRWT and PRLRI146L homo and
heterodimerize.
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FIGURE 3 | Blue native gel electrophoresis reveals that
membrane-associated PRLRWT and PRLRI146L mainly exist in two
oligomeric states. (A) Solubilized membrane extracts of HL-5 cells were
resolved by BN-PAGE and PRLR complexes were identiﬁed by αPRLR
immunoblotting. In control conditions (CTL), PRLRWT and PRLRI146L
exhibited similar migration proﬁles composed of two main bands (labeled
 and ). Of the various denaturing conditions that were tested (urea,
heating, DTT, and DDM), heating is the only one that signiﬁcantly modiﬁed
the migration proﬁle as the PRLR migrated as a single band, assigning the
latter to the monomeric form (). Samples treated with DDM were also
analyzed by SDS-PAGE to ensure equal loading. (B)To determine whether
the expression levels of the PRLR affected receptor stoichiometry, we
compared stable clones expressing high (HL-5 clone) or low (Ba/F-LP
population) levels of PRLR; non-transfected HEK 293 cells were used as
negative control. Although the autoradiography shown for Ba/F 3 samples
had to be over-exposed to detect the PRLR, the migration proﬁle was
qualitatively similar irrespective of PRLR expression levels. (C)The effect of
ligand binding on the formation of receptor complexes was analyzed by
adding PRL or Del1-9-G129R-hPRL antagonist (antago) to HL-5 cells. None
of these conditions signiﬁcantly altered the migration proﬁle.
form of the receptor (Figure 3A). This indicated that the upper
band corresponded to a non-covalent complex, while the absence
of effect of the other denaturing conditions suggested that this
αPRLR-immunoreactive complex was very stable. Accordingly,
urea concentration up to 4M was necessary to disrupt this com-
plex (data not shown). The exact nature of this larger complex
could not be deﬁnitely demonstrated. Although it is likely that
it corresponded to PRLR homodimers, one cannot exclude the
possibility that this band also contained PRLR complexed to well
identiﬁed receptor-associated-partners, e.g., JAK2, MAPK, or Stat
proteins. However, re-blotting the membranes to identify any of
these partners was unsuccessful.
In order to assess that PRLR pre-association did not result
from forced receptor clustering due to over-expression in transient
transfections, we compared the HL-5 clone (60,000 hPRLRWT per
cell; Kinet et al., 1999) to so-called Ba/F-LP, a previously described
Ba/F3 cell population expressing less than 500 hPRLRWT per
cell (Bernichtein et al., 2003a). As shown on Figure 3B, PRLR
complexes extracted from both cell lines exhibited similar stoi-
chiometries in native conditions, as the two major bands were
again detected. Finally, in agreement with co-IP experiments,
activation of PRLRWT by hPRL, or receptor blockade by Del1-9-
G129R-hPRL antagonist, did not detectably modify the migration
proﬁle (Figure 3C).
Taken together, these experiments suggest that (i) membrane-
anchored hPRLRWT exists in two main oligomeric states, presum-
ably corresponding to monomeric and dimeric forms, (ii) the
larger complex is highly stable and does not result from forced
clustering, and ﬁnally (iii) neither triggering nor blockade of the
receptor affect the apparent stoichiometry of PRLR complexes.
USE OF BRET TO EVALUATE DISTANCE/ORIENTATION MODIFICATION IN
PREFORMED hPRLRWT AND hPRLRI146L HOMODIMERS UNDER hPRL OR
ANTAGONIST BINDING
As BN-PAGE analysis failed to detect any signiﬁcant change in the
native stoichiometry of membrane-associated PRLR under PRL
or antagonist binding, we asked whether ligand binding could
affect the conformation of preformed PRLR dimer, either WT or
I146L, and whether the type of ligand could affect the results. As
stated in the Introduction, recent BRET1 studies have suggested
that PRL binding to PRLRWT does not induce detectable ﬂuores-
cence changes (Qazi et al., 2006). We ﬁrst aimed at conﬁrming we
were able to reproduce that data.
Saturation BRET experiments allow to determine BRET50 val-
ues, which discriminate receptor recruitment from a preformed
dimer (Mercier et al., 2002). As shown in Figure 4A, no difference
in BRET50 values could be observed for PRLRWT between basal
(BRET50 = 2.0± 0.7) and activated states (BRET50 = 2.4± 0.8),
in full agreement with previous reports (Qazi et al., 2006). We
further showed that receptor blockade using the pure antagonist
Del1-9-G129R-hPRL also failed to alter BRET50 value (2.7± 0.9).
Further analyses of activation or blockade of homo- and hetero-
paired PRLRWT or PRLRI146L were therefore performed in two
transfection conditions only (4:1 and 8:1 PRLR–YFP/PRLR–Rluc
ratios). In these conditions, neither PRL nor the antagonist sig-
niﬁcantly altered BRET signals compared to non-stimulated cells,
whatever the receptor pairs involved (Figure 4B).
It is well known that a large part of the PRLR pool resides
inside the cell. We reasoned that BRET signals involving intracel-
lular PRLR may partly mask BRET changes affecting cell surface
receptors upon ligand binding. In order to increase the number
of receptors accessible to the ligands, we repeated these experi-
ments in the presence of 0.015% of saponin, a molecule known to
permeabilize biologicalmembranes (Couturier and Jockers,2003).
This effect of saponin was displayed by increased basal PRLR–Rluc
signals presumably reﬂecting higher accessibility of intracellu-
lar receptors to coelenterazine (Figure 4C, top panel). As in the
meantime we also observed that saponin intrinsically affectedYFP
ﬂuorescence (Figure 4C, middle panel), this resulted in a slight
decrease of absolute BRET levels (Figure 4C, lower panel). Despite
membrane permeabilization, BRET assays of activation or block-
ade of either homo- or hetero-paired PRLR revealed no difference
compared to the basal state (Figure 4D).
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FIGURE 4 | Analysis of PRLR activation and blockade using BRET1. (A)
Saturation BRET assays of homo-paired PRLRWT (n =3). HEK 293 cells were
co-transfected using a constant amount of PRLR–Rluc plasmid (25 ng per well)
and increasing amounts of PRLR–YFP plasmid (0–200 ng per well). Ratios are
indicated on the X axis. BRET signals were detected in basal conditions and
15min after stimulation using 1μg/mL PRL or 10μg/mL Del1-9-G129R-hPRL
antagonist. Data are represented as the mean of percentage of maximal
BRET signal (Bmax) calculated for each stimulation condition. (B) BRET assays
were performed for homo and heterodimers of PRLRWT or PRLRI146L at 4:1 and
8:1YFP/Rluc conditions. BRET signal was detected after 15min of PRL or
antagonist stimulation in PBS. Data are represented as the mean of
percentage of basal condition (n =4). (C) Luminescence of PRLR–Rluc
(a.u.= arbitrary unit, top panel), total ﬂuorescence of PRLR–YFP (middle
panel) and normalized BRET (bottom panel) were measured in transfected
HEK cells after a 15-min incubation in the presence or not of 0.015% saponin.
As similar results were obtained for all receptor combinations, only data
obtained using non-stimulated PRLRWT are shown. (D) Idem as in B, but for
BRET assays performed in the presence of 0.015% saponin (n =4).
In conclusion, in agreement with previous studies as well as
with all the experiments reported above, these data are not in favor
of receptor recruitment as being the principal mechanism medi-
ating PRLR activation. Rather, they suggest that ligand-mediated
receptor activation or blockade involves rearrangements within
preformed PRLR complexes upon ligand binding. These could
involve conformational changes of cytoplasmic tails that could
not be detected in this study due to the intrinsic limitations of
BRET procedures.
USE OF TR-FRET TO DETECT PREFORMED hPRLRWT AND hPRLRI146L
HOMODIMERS
As both hPRLRI146L and hPRLRWT appeared to be equally and
constantly dimerized in all tested conditions (unbound, activated,
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or blocked), we turned to a sensitive approach able to detect dis-
tance changes between interacting proteins, namely TR-FRET.
The speciﬁc reactive ﬂuorophore concentration used for ratio-
metric labeling of ST-PRLR was determined by ﬂuorophore
titration and FRET signal detection, as shown on Figure 5A.
The ability of SNAP-ﬂuorophores to speciﬁcally label cell sur-
face ST-PRLR was also assessed by confocal imaging, e.g., using
SNAP-Green (Figure 5B). As this was the ﬁrst time this tech-
nology was applied to a member of the cytokine receptor super-
family, FRET signals obtained for the PRLRWT were compared
to those obtained for a seven transmembrane domain GPCR
(mGluR2) and a single transmembrane domain Immunoglob-
ulin receptor (CD4) earlier characterized using this approach
(Maurel et al., 2008). As shown in Figure 5C, COS-7 cells tran-
siently expressing exogenous ST-PRLR exhibited FRET signals
that were in the range of signals obtained for the two con-
trol receptors, suggesting the reliability of this method when
applied to the PRLR. Finally, the speciﬁcity of PRLR FRET sig-
nals was assessed by co-expressing receptors lacking the SNAP
tag. As shown on Figure 5D, expression of HA-PRLR markedly
decreased FRET signals obtained using ST-PRLR due to the for-
mation of HA-PRLR/ST-PRLR heterocomplexes. In contrast, high
FIGURE 5 | Application ofTR-FRET technology to the PRLR. (A)
Determination of ﬂuorophore concentration for equimolar ratio of PRLR
labeling using a given ﬂuorophore pair. Variations in FRET signals using
PRLRhigh stable cell lines (characterized on Figure 6) are shown as a function
of acceptor ﬂuorophore concentration. Cells were incubated 1 h at 37˚C in the
presence of 100 nM of SNAP-Lumi4Tb and of increasing concentrations of
SNAP-Red (left panel) or SNAP-Green (right panel). Maximal Δ665 signal
[(S665)Donor+Acceptor − (S665)Donor] is representative of ﬂuorophore concentration
that gives same quantity of PRLR labeled with donor or acceptor. The optimal
concentrations ratio was obtained for 100 nM of SNAP-Lumi4Tb with 500 nM
of SNAP-Red and 100 nM of SNAP-Lumi4Tb with 100 nM of SNAP-Green.
Data obtained for PRLRWT and PRLRI146L are represented in gray and black,
respectively. (B) Confocal imaging of PRLRhigh stable clones after 1 h (4˚C)
labeling using SNAP-Green ﬂuorophore. (C) COS-7 cells were transfected
using plasmids encoding ST tagged receptors (PRLR, mGluR2, and CD4),
then labeled 48 h later using 100 nM SNAP-Lumi4Tb alone or in combination
with 500 nM SNAP-Red. Signals at 620 or 665 nm were measured, and FRET
signals (ΔR) were determined as detailed in Section “Materials and
Methods.”The amplitude of FRET signals obtained for each receptor at similar
expression level as determined by speciﬁc ﬂuorescence values at 620 nm
(S620) are represented. (D) COS-7 cells were co-transfected using plasmids
encoding ST-PRLR (in all conditions) and, as indicated, empty vector (mock),
HA-PRLR or HA-CD4 plasmid. Left bars represent the expression level of cell
surface HA-receptors as determined using anti-HA ELISA (arbitrary units,
a.u.). Right bars represent FRET signals (using 100 nM SNAP-Lumi4Tb and
500 nM SNAP-Red) involving ST-PRLR homodimers in the three experimental
conditions, as represented on the right. Values were normalized to the FRET
signal obtained for ST-PRLR+empty vector condition.
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level expression of HA-CD4 had no effect on ST-PRLR FRET
signals.
Next, COS-7 cells were transiently transfected using increas-
ing amounts of HA-ST-PRLRWT or HA-ST-PRLRI146L encoding
vectors. Cell surface expression of PRLR proteins was quantiﬁed
by labeling cell surface SNAP tags using SNAP-Lumi4 Tb alone
and measuring ﬂuorescence at 620 nm (Figure 6A, left panel).
A good correlation could be observed between the amount of
transfected plasmid and the ﬂuorescence emitted by tagged PRLR
(WT or I146L). FRET signals were then measured at 665 nm
following double labeling of ST-PRLRs using SNAP-Lumi4 Tb
and SNAP-Red ﬂuorophore pair. Normalized FRET was calcu-
lated as the ratio between speciﬁc ﬂuorescence at 665 nm (FRET
signals) and the speciﬁc ﬂuorescence at 620 nm (reﬂecting the
number of cell surface PRLRs). As shown on Figure 6A (right
panel), normalized FRET obtained in the absence of stimulation
was not affected by the level of receptor expression. Since tran-
sient transfections could possibly mask minor variations of FRET
signals due to heterogeneous expression levels of PRLR between
the various wells, we aimed at conﬁrming these ﬁndings using
stable clones. Several geneticin-selected clones of HEK 293 cells
expressing HA-ST-PRLRWT or HA-ST-PRLRI146L were character-
izedusing (i) ST labeling andαPRLRwestern blotting to determine
relative PRLR expression levels between the various clones, and
(ii) phospho-Stat5 immunoblot to ensure PRL-responsiveness as
shown in Figure 1B (data not shown). Based on these analyses,
two stable clones to be used for further TR-FRET studies were
selected for each receptor based on their high (PRLRhigh) versus
low (PRLRlow) level of receptor expression (Figure 6B, left panel).
As observed above using transient transfections, normalized FRET
signals were very similar for all clones (Figure 6B, right panel), fur-
ther conﬁrming that the basal FRET detected for non-stimulated
receptors (WT or I146L) was not affected by the expression level
of the latter.
Taken together, these results demonstrate that FRET signals
observed for non-stimulated receptors reﬂect speciﬁc physical
interactions and do not result from random collisions of labeled
receptors due to over-expression. Therefore, for convenience of
FRET detection, due to higher ﬂuorescence levels, the experiments
reported below were performed using the PRLRhigh clones.
USE OF TR-FRET TO MONITOR DISTANCE CHANGES WITHIN hPRLRWT
OR hPRLRI146L HOMODIMERS FOLLOWING RECEPTOR TRIGGERING OR
BLOCKADE
In order to assess TR-FRET methodology could be used to eval-
uate the effect of ligand binding on receptor conformation, we
ﬁrst monitored ligand–receptor interaction using TR-FRET bind-
ing assays. To that end, hPRL was randomly labeled on exposed
lysines using Red ﬂuorophores, and receptors (HA-ST-hPRLRWT
or HA-ST-hPRLRI146L) were labeled on ST using SNAP-Lumi4 Tb
as described above. Stimulations were performed at room temper-
ature, and ligand-receptor FRET signals were recorded for 24 h.
FIGURE 6 | Constitutive dimerization of cell surface PRLRWT and PRLRI146L
as determined byTR-FRET is independent of receptor expression level
and cell type. (A) Increasing amounts of plasmids encoding PRLRWT or
PRLRI146L TR-FRET constructs were transiently transfected into COS-7 cells.
Increasing levels of PRLR protein expression was conﬁrmed by measuring
the level of ﬂuorescence emitted by cells labeled with the ﬂuorescence donor
only (S620, left panel). Whatever the level of PRLR expressed at the cell
surface, normalized FRET ratios measured after labeling with SNAP-Lumi4Tb
and SNAP-Red ﬂuorophore combination were unchanged (right panel). (B)
Similar experiments were performed using stable HEK 293 clones expressing
either low (PRLRlow) or high (PRLRhigh) levels of HA-ST-PRLR (WT or I146L) as
determined by 620 nm ﬂuorescence [see (A)]; parental HEK 293
(undetectable levels of endogenous PRLR) and HL-5 clone (high level of
untagged exogenous PRLR) were used as negative controls. Normalized
FRET signals obtained after labeling these clones using SNAP-Lumi4Tb and
SNAP-Red ﬂuorophore combination were similar, irrespective of PRLR
expression levels (right panel). Results are representative of at least three
independent experiments performed in triplicate.
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Although FRET signals reached the equilibrium (maximal values)
after 17–20 h (data not shown), KD values could be calculated
from much shorter times without being affected by longer incu-
bations (dose–responses reported inFigure 7Awere obtained after
3 h incubation). Curve ﬁttings performed using the “one speciﬁc
binding site model” revealed KD values of ∼4 nM for hPRL to
both hPRLRWT and hPRLRI146L (Table 1), which is in good agree-
ment with afﬁnities calculated using classical 125I-hPRL receptor
FIGURE 7 | PRLRWT or PRLRI146L triggering does not affect receptor
dimerization. (A) PRLRhigh stable cell lines were labeled using
SNAP-Lumi4Tb (100 nM), then stimulated with increasing doses of
Red-labeled hPRL (left panel) or antagonist (right panel) alone (solid lines) or in
the presence of excess non-labeled PRL (dotted lines), as indicated. FRET
signal corresponding to ligand–receptor interaction was detected along time
at RT (3 h stimulation is represented). Curve ﬁtting was performed using a
1-site binding algorithm to determine K D values. (B,C)TR-FRET assay of
homo-paired ST-PRLRWT and ST-PRLRI146L. COS-7 cells were transiently
transfected using plasmids (0.2μg/well) encoding either receptor as
indicated (mock: empty plasmid). Forty-eight hours later, ST-PRLRs
were labeled (1 h, 37˚C) using SNAP-Lumi4Tb (100 nM) and
SNAP-Red (500 nM; R0 of 58Å). Time-course [PRL or antagonist 43 nM
(B)] and PRL or antagonist dose-response [15min (C)] stimulations were
performed, which did not affect FRET signals for either PRLR. (D)TR-FRET
signals of receptor triggering by addition of PRL (0–220 nM, 3 h, RT), obtained
using 100 nM SNAP-Lumi4Tb and 100 nM SNAP-Green ﬂuorophores
(R0 =46Å) failed to signiﬁcantly affect FRET signals. Results are
representative of at least three independent experiments performed in
triplicate.
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Table 1 | Binding affinities of hPRL and Del1-9-G129R-hPRL to PRLRWT
and PRLRI146L usingTR-FRET binding assays.
KD (nM)
PRL-red Antagonist-red
PRLRWT 3.84±0.38 23.60±2.73
PRLRI146L 4.62±0.55 30.68±3.92
assays (Bernichtein et al., 2003b). This experiment demonstrated
that (i) PRL does interact with tagged receptors with the same
afﬁnity as previously documented for untagged PRLRWT, and
(ii) ligand/receptor interactions are detected shortly after ligand
addition, and binding afﬁnities can be reliably measured after 3 h
incubation at RT, which is the condition that was used for the
dose–response experiments described below.
We then used TR-FRET to investigate whether any distance
change occurred between predimerized PRLR moieties upon PRL
binding. Time-course and dose-dependent hPRL stimulations
were performed for both receptors, ﬁrst using transiently trans-
fected COS-7 cells (Figures 7B,C). FRET signals (ΔR) obtained
using SNAP-Lumi4 Tb+ SNAP-Red ﬂuorophore pair remained
unchanged in comparison to baseline, irrespective of the time
elapsed after stimulation (we tested 0–3 h at RT, 0–15min time-
frame with 43 nM of ligand is shown on Figure 7B) or the
concentration of agonist or antagonist (0–43 nM), and this was
true for both PRLRWT and PRLRI146L. The slightly lower values of
ΔR signal obtained for hPRLRWT compared to hPRLRI146L clones
presumably reﬂects the lower level of receptor expression in the
former (Figure 6B). All these observations were strictly identi-
cal whether stimulations were performed at room temperature or
37˚C (data not shown). We then aimed at repeating these exper-
iments using stable cell lines in order to avoid any interference
of possible heterogeneous PRLR expression in transient trans-
fections. Using PRLRhigh stable clones described in Figure 6B,
we fully conﬁrmed that PRLR triggering failed to affect FRET
signals for either receptors (Figure 7C). Finally, as subtle dis-
tance modiﬁcations resulting from conformational adjustments
can sometimes be detected using one ﬂuorophore pair and not
with another, we aimed at using another ﬂuorophore. Thanks
to the spectral properties of terbium cryptate that exhibits a
multi-peak emission spectrum, combination of various accep-
tors are possible with this lanthanide. The Förster distances (R0)
of ﬂuorophore pairs consisting of SNAP-Lumi4 Tb+ SNAP-Red
or SNAP-Green are 58 and 46Å, respectively, which falls within
the distance range of interacting proteins. The use of SNAP-
Lumi4 Tb+ SNAP-Green pair (Figure 7D) produced lower values
of FRET ΔR compared to SNAP-Lumi4 Tb+ SNAP-Red pair,
which is strictly dependent on spectral properties of these ﬂuo-
rophores. No modiﬁcation of ΔR was noticed under a wide range
of hPRL concentration (Figure 7D), irrespective of the receptor
involved.
We then conducted similar experiments using the pure PRLR
antagonist Del1-9-G129R-hPRL as the ligand in order to deter-
mine whether the outcome of receptor blockade (i.e., using a
ligand able to bind but not to activate the PRLR) differed from
that described above for receptor triggering. TR-FRET binding
assays conﬁrmed the interaction between the antagonist and the
ST-PRLRs (WT or I146L; Figure 7A, right panel), and again, afﬁn-
ity values calculated using this method were very similar to those
obtained using classical radioreceptor assays, i.e., one log lower
compared to hPRL (Table 1). Similar to hPRL binding, antago-
nist binding failed to affect TR-FRET signals, whether time-course
(Figure 7B), dose–response (Figure 7C), or ﬂuorophore pairs with
different R0 (data not shown) were involved.
Taken together, the data reported in Figures 4–7 (i) conﬁrm
that no distance variation and/or reorientation of homodimerized
PRLRWT intracellular domains (ICD) is detectable using BRET1
following receptor activation, and reveal that (ii) there is no major
distance variation between the N-termini of unbound or liganded
homodimerized PRLR chains. Importantly, these experiments dis-
criminated neither PRL from the antagonist, nor PRLRI146L from
the wild type receptor.
DISCUSSION
Our group has been long involved in the development of PRLR
antagonists (Gofﬁn et al., 1996a, 2005; Bernichtein et al., 2003b).
These studies led to the design of a pure PRLR antagonist (Del1-
9-G129R-hPRL) that was shown to be a potent inhibitor of PRLR
signaling mediated by endocrine as well as autocrine PRL, using
both in vitro (for a review Bernichtein et al., 2010) and very
recently, in vivo (Rouet et al., 2010) models. Furthermore, we
reported in 2008 the ﬁrst functional genetic PRLR variant asso-
ciated with a human disease. This missense mutation encodes
I146L substitution in the ECD, leading to a constitutive basal
activity that is not always easily detected at the molecular level
(Gofﬁn et al., 2010), but anyway sufﬁcient to immortalize sta-
bly transfected Ba/F3 cells (Bogorad et al., 2008; Courtillot et al.,
2010). Interestingly, this ligand-independent basal activity is abro-
gated by Del1-9-G129R-hPRL,which then acts as a reverse agonist
(Bogorad et al., 2008). The aim of this study was to progress in
the understanding of the molecular mechanisms involved in ago-
nist or I146L-mediated receptor activation, and antagonist-driven
receptor blockade.
It is currently accepted that the active form of the PRLR is a
homodimer. This model relies on structural (Elkins et al., 2000;
Broutin et al., 2010), biophysical (Sivaprasad et al., 2004; Jomain
et al., 2007), biochemical (Gadd and Clevenger, 2006), and muta-
genesis/functional (Gofﬁn et al., 1994, 2005; Gadd and Clevenger,
2006; Langenheim et al., 2006) evidence that agonist ligands inter-
act with two PRLR moieties. Accordingly, experiments involving
ECDs (SPR, crystallogenesis; Jomain et al., 2007; Svensson et al.,
2008) showed that functional abolition of binding site 2 prevented
antagonists from interactingwith the second receptormoiety (they
only form 1:1 complexes via binding site 1). Recent studies have
addressed whether dimerization of membrane-anchored PRLR
was constitutive or ligand-induced. In other words, they inves-
tigated whether receptor activation involved (i) clustering of two
monomeric receptors to form a homodimer, following the sequen-
tial dimerization model initially suggested (Fuh et al., 1992; Gofﬁn
et al., 1994; Figure 8A), or (ii) conformational rearrangements
within preformed dimers (Figures 8B–D). Clearly, the current
consensus is in favor of the latter model (Gadd and Clevenger,
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FIGURE 8 | Hypothetic models of preformed PRLR homodimer triggering
by PRL.The various models of cytokine receptor activation discussed in the
text are illustrated. (A–D) Represent the unbound states, while panel E
corresponds to the liganded receptor. In (A–D), two PRLR-ECDs are
represented each as two black rectangles, corresponding to subdomains D1
and D2. The potential space occupancy of the SNAP tag is represented by a
gray circle whose size was predicted based on the 3D structure of
O6-benzyl-guanine transferase (PDB: 2JEG), the enzyme from which SNAP
tag is derived. The 30-Å value corresponds to the distance between the active
site of the enzyme (which traps the ﬂuorophore in the case of the SNAP tag)
and the C-terminus, which is fused to the N-terminus of the PRLR-ECD. (A)
Sequential dimerization of PRLR induced by the ligand. In this model, the
distance separating the two PRLR moieties before ligand binding is expected
to be much higher than 100Å, i.e., beyond the detection limit of RET
technologies. (B)This model of predimerized receptor was proposed for the
IL-4R. Although D2 domains of each monomer are in close proximity, D1
domains are distant from each other. After ligand binding, D1 domains are
supposed to undergo conformational changes leading to reduced D1–D1
distance within the receptor dimer. (C)This model was proposed for an
engineered cysteine-mutated SF1b PRLR variant. In this model, the PRLR
exists as a preformed dimer in which D1 and D2 domains are aligned. In
contrast to model B, ligand binding is assumed to move both D1 domains
away from each other. (D)This ﬁnal model of predimerized receptor has been
proposed for the GHR. In this model, the distance between D1 domains is
relatively constant irrespective of ligand binding. Receptor activation involves
conformational and subtle intrinsic structural changes that are not detectable
by RET approaches. (E)The crystal structure of the trimeric hPRL/rPRLR-ECD2
complex (PDB: 3NPZ) is represented. Distances were determined using the
PyMOL Molecular Graphics System (DeLano, 2002; LLC, San Carlos, CA,
USA) and the program Coot (Emsley and Cowtan, 2004).
2006;Qazi et al., 2006).However, the actualmechanismof receptor
triggering is still uncertain as the putative rearrangements induced
by agonists are yet to be identiﬁed. BRET2 studies involving C-
terminal tagged PRLRhave indicated that agonist binding (natural
or engineered ligands) was required to generate detectable BRET
signals,whilemild antagonists failed to do so (Tan et al., 2005; Lan-
genheim et al., 2006). According to the predimerized model, such
data can be interpreted as evidence that agonists induce conforma-
tional changes propagating from the ECD to the intracellular part
of the receptor, leading both C-terminal tails to orient in sufﬁcient
proximity to permit energy transfer (see below). However, such
data are not incompatible with a model of sequential dimeriza-
tion in which agonists, but not antagonists, would be able to bring
together two receptor moieties. Otherwise, BRET1 studies involv-
ing any isoform of the PRLR (Qazi et al., 2006; Xie et al., 2009)
have shown that basal BRET signals were detectable without hor-
mone stimulation, suggesting that C-terminal tails of unbound
receptors are actually at distance compatible with energy trans-
fer, which is in favor of the predimerized model. In addition, as
classical FRET/BRET signals are directed by two distinct parame-
ters – distance and respective dipole orientation of ﬂuorophores
(Pﬂeger and Eidne, 2006) – simultaneous modiﬁcations of both
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parameters can theoretically compensate each other and mask
conformational changes. These few examples highlight the difﬁ-
culty of interpreting data obtainedusing classical resonance energy
transfer technologies.
The results of our co-IP experiments (Figure 2) are in good
agreement with those earlier reported by others (Gadd and Cle-
venger, 2006), who suggested that receptor dimers exist prior
to ligand binding. Our observations further strengthened the
hypothesis that the activation state of the PRLR is not related to
its dimerization state, at least from what can be deduced by dena-
turing electrophoresis (SDS-PAGE). Indeed, our data deﬁnitely
discarded the possibility that the pure antagonist Del1-9-G129R-
hPRL acted by disrupting receptor homodimerization (while its
antagonistic effect was assessed in control phospho-Stat5 experi-
ments, data not shown). According to a previous study showing
that the partial antagonist G129R-hPRL failed to induce BRET
signals (while PRL did; Tan et al., 2005), our ﬁndings support the
hypothesis that antagonists induce either no, or different confor-
mational changes compared to those accompanying activation of
the receptor by agonists (see below). We also demonstrated that
the ability of PRLRI146L to homodimerize was undistinguishable
from that of PRLRWT (in the presence or in the absence of ligand),
suggesting that I146L mutation does not detectably alter the fre-
quency and/or stability of receptor–receptor interactions. Finally,
we provided evidence that PRLRI146L and PRLRWT are able to
heterodimerize. The functional properties of such heterodimers
are at present unknown. We can notice that constitutive signal-
ing was observed in a reconstituted “heterozygous” experimental
model involvingMCF-7 cells expressing endogenous PRLRWT and
exogenous PRLRI146L (Bogorad et al., 2008). This model provides
evidence that basal activity of PRLRI146L is not abolished in the
presence of PRLRWT, but is certainly not a proof that it ismediated
by heterodimers. Further investigations are warranted since all
patients identiﬁed to date exhibited heterozygous proﬁle regarding
the mutation (Bogorad et al., 2008; Courtillot et al., 2010).
Antagonist-mediated receptor blockade and I146L-mediated
receptor triggering are two activity-related events that originate
from the ECD of the PRLR. As none of these situations seemed
to affect receptor dimerization per se, it was relevant to inves-
tigate how the conformation of the ECD could potentially be
affected. To address this question, we used TR-FRET technology,
which presents two major advantages over classical FRET/BRET
approaches. First, as TR-FRET signals are only directed by dis-
tances between ﬂuorescent tags, any FRET variation can be trans-
lated as a distance change between ﬂuorophores, without any risk
of misinterpretation. Second, as ﬂuorophores speciﬁcally label cell
surface receptors,TR-FRET is particularly appropriate to followup
distance modiﬁcations between homodimerized ECDs that would
be induced by ligand binding. The existence of FRET signals in
the absence of stimulation ﬁrst indicated that SNAP tags linked
to receptor ECDs are at distances compatible with energy trans-
fer (<100Å). Relative FRET signals were independent of PRLR
expression levels, arguing for the speciﬁcity of the signal observed.
PRLRI146L and PRLRWT produced similar levels of FRET, sug-
gesting they do not distinguish from each other by the distance
separating ECDs of homodimerized receptor. All these observa-
tions agree with, and complement biochemical studies conﬁrming
that unbound receptors (WT and I146L) are in close proximity
at the cell surface, and supporting their existence as preformed
homodimers. Second, and more important, the addition of hPRL
or Del1-9-G129R-hPRL failed to modify the intensity of FRET
signals in all the conditions tested, including time-course and
dose-dependent experiments, and this was true for both recep-
tors. Furthermore, we used two different ﬂuorophore pairs (with
different R0) to rule out the possibility that the absence of FRET
signal modiﬁcation could be related to the intrinsic characteristics
of ﬂuorophores (Figures 7C,D). In these studies, the actual occur-
rence of ligand–receptor interactions was conﬁrmed in control
binding experiments involving energy transfer between labeled
ligands and receptors, ruling out any technical issue (Figure 7A).
Taken together, these data indicate that receptor activation
and blockade do not correlate with detectable distance changes
between the homodimerized ECDs compared to the unbound
state. As TR-FRET involves cell surface labeling, i.e., the popu-
lation of receptor that speciﬁcally interacts with the ligands, these
data deﬁnitely discard the sequential model of PRLR dimerization
(Figure 8A). The two crystal structures of PRL/PRLR-ECD2 com-
plexes thatwe recently reported (Broutin et al., 2010;VanAgthoven
et al., 2010) indicate that the N-termini of the two ECDs are 112Å
away from each other in the crystals (Figure 8E). It could be
tempting to speculate that this distance applies to the ECDs of the
membrane-anchored receptor, either bound or unbound. How-
ever, the actual distance between membrane PRLR-ECDs could
not be experimentally determined in this study, since FRET sig-
nals are mediated by ﬂuorophores that are covalently linked to
SNAP tags, the exact position of which relative to PRLR-ECDs is
unknown. However, it is clear that these tags fold outside ligand
binding sites, since binding afﬁnities (Figure 7A) and signaling
capacities (Figure 1B) of ST-PRLRs were not affected by the pres-
ence of the tag. Regarding binding, the afﬁnities determined by
ligand–receptor TR-FRET (Figure 7A) perfectly matched previ-
ously reported values (Kinet et al., 1999; Bernichtein et al., 2003b),
which brings a proof-of-concept that this non-radioactive tech-
nology involving labeled PRL could be used as an alternative
methodology to classical binding assays involving 125I-PRL.
Various models of structural ECD ﬂexibility have been pro-
posed for cytokine receptors (Figures 8B–D), that can be used to
speculate on the mechanism of PRLR activation. Three of them
are shortly discussed below. The type I IL-4 receptor is an het-
erocomplex involving the cytokine-speciﬁc IL-4 Rα chain and
the common γ chain. Weidemann et al. (2007) have proposed
a model (Figure 8B) in which the tryptophans of the highly con-
served WS motif of each receptor moiety interact with the lipid
membrane in the unbound state, providing an “open” conforma-
tion (“off-state”) of the ECD heterocomplex. This conformation
is assumed to be released upon ligand binding to IL-4 Rα before
bringing the γ chain ECD into a “closed” conformation locked by
the cytokine (“on-state”). As such a model involves large mod-
iﬁcations of the ECD–ECD distance which should result in big
variations of TR-FRET signals, we believe it does not apply to the
PRLR.
Dufau’s group recently proposed a somehow opposite model
for a short PRLR (SF1b) mutant lacking the two internal disulﬁde
bonds within the D1 subdomain of the ECD (Figure 8C). Given
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the general importance of intramolecular disulﬁdes in protein
folding, such a mutant is expected to exhibit marked conforma-
tional alteration (its actual 3D structure is unknown).Accordingly,
it is no longer able to bind PRL (Rozakis-Adcock and Kelly, 1991;
Xie et al., 2009). In addition, this mutant was found to have lost
its dominant-negative activity toward the long isoform, which
correlated with its inability to heteromerize with the latter (Xie
et al., 2009). Computer modeling based on the oPL-PRLR2 crys-
tal structure (Elkins et al., 2000) suggested that structural changes
affecting D1, although not drastic, could lead to a reorientation
of D1 with respect to D2 domains (basically, they are predicted to
align), which could result in stabilization of the mutant homod-
imer due to interactions between D1 domains. At ﬁrst sight, such
a model could have applied to PRLRI146L, since receptor homod-
imer stabilization was a reasonable starting hypothesis to explain
the higher basal activity of this natural variant (Bogorad et al.,
2008). It is very unlikely, however, as PRLRI146L exhibits two major
differences with this SF1b cysteine mutant: it binds PRL with high
afﬁnity (Figure 7A) and it heterodimerizes with PRLRWT. Even
if one hypothesized that PRLRI146L could adopt such an aligned
D1–D2 conformation in the unbound state while remaining able
to interact with PRL, hormone binding would imply the opening
of theECDhomodimer to reach the known structure of the ternary
complex (Figure 8C). This would likely produce signiﬁcant FRET
signal modiﬁcations that were not experimentally observed.
Finally, the third model is the one proposed for GHR (Brown
et al., 2005) and EPOR (Remy et al., 1999), two mono-type
cytokine receptors. Like the PRLR, both have been proposed
to be dimerized prior to ligand binding. Concerning the GHR,
Waters and colleagues proposed that receptor–receptor cluster-
ing in the unbound state is mainly mediated by transmembrane
domain interactions, resulting in a close proximity of the D2
domains of the two monomers (Figure 8D). In this model, the
ligand is assumed to induce relative rotational/translational move-
ment of subunits within the receptor dimer, without detectable
changes in ECD conformation as determined using classical FRET.
These rotational movements involving no major distance alter-
ation between both receptor chains would propagate toward the
cytoplasmic domain, leading receptor-associated JAK2 kinases
into close proximity (Brown et al., 2005). The EPORmodel slightly
differs from the latter as D2 domains have been proposed not to
interact in the unbound state. Ligand binding is assumed to bring
both D2 and downstream transmembrane/cytoplasmic domains
at shorter distances, in a scissor movement, allowing Jak kinases
to interact, and to transphosphorylate (Remy et al., 1999).
Our results for PRLR suggest some similarities with the activa-
tion mechanisms proposed for these two closely related receptors.
In particular, it has been proposed that transmembrane domains
play an essential role in stabilizing unliganded homodimers (Gadd
and Clevenger, 2006). Nevertheless, as genetic manipulations of
the PRLR similar to those performed in the GHR to support
the rotational/translational model failed to achieve similar results,
this suggests that these two receptors exhibit some differences in
their mechanism of activation (Liu and Brooks, 2011). Compari-
son of free and bound 3D structures of PRLR agonists/antagonist
released within the past 3 years have provided clues to the subtle
changes occurring in the hormone and the ECD upon receptor
activation (Jomain et al., 2007; Svensson et al., 2008; Broutin et al.,
2010; Van Agthoven et al., 2010). The 3D structure of PRLRI146L
is hoped to reveal whether some of these ligand-induced struc-
tural changes are intrinsically present in the receptor mutant. Also,
determining how these minor structural rearrangements prop-
agate to the cytoplasmic domain needs to be addressed for the
PRLR. In this respect, a general trait of BRET1 studies involv-
ing C-terminal tagged cytokine receptors (OBR, GHR, PRLR) is
that BRET signals are higher for short/truncated compared to long
receptor isoforms (Couturier and Jockers, 2003; Brown et al., 2005;
Qazi et al., 2006). In addition, for OBR, an effect of ligand bind-
ing is observed using short isoforms only (Couturier and Jockers,
2003). As the constitutive activity of the I146L genetic variant
has only been demonstrated for the long receptor (Bogorad et al.,
2008), our study exclusively focused on that isoform. Therefore, it
may not be surprising that we detected no signiﬁcant changes in
BRET signals upon activation. The larger size of the long receptor
cytoplasmic domains may indeed offer a higher degree of ﬂexi-
bility to C-terminal tags, which could interfere with the detection
of conformational changes driven by the ECD. As no 3D struc-
ture of any cytokine receptor cytoplasmic domain is available, it
is very difﬁcult to speculate on distance parameters, and varia-
tion thereof, between two receptor chains. For all these reasons, it
would certainly be misleading to interpret the absence of strong
BRET signal variation as the evidence for the absence of struc-
tural rearrangement in the cytoplasmic domain of PRLRWT and
PRLRI146L.
Although structural and functional data provide evidence
that the PRLR is a homodimer, the occurrence of higher order
oligomers was still to be investigated. We used non-denaturing
blue native electrophoresis to address this question. This approach
revealed the existence of two major forms, whose molecular mass
could not be deﬁnitely assessed using reference membrane pro-
teins of known molecular mass. However, the fact that only the
faster migrating band persisted after heat denaturation supported
that the latter corresponded to the monomeric receptor. The slow-
migrating complex was tentatively assigned to the homodimer
evidenced by FRET and co-IP studies. One could have expected
complexes involving the receptor associated with signaling pro-
teins to be detected using this experimental approach. However,
membrane blotting using Stat5 or JAK2 antibodies failed to reveal
these proteins, suggesting either that such interactions are too
transient or not sufﬁciently stable to persist along sample prepara-
tion, or that such complexes represent a minority of membrane-
bound PRLR that are below detection threshold, or perhaps that
epitopes of these native receptor-associated proteins were not
accessible. Taken together, our result do not provide evidence
for the existence of receptor oligomers (tetramers, . . .), although
this negative result should not be interpreted as a proof of their
non-occurrence. Further studies involving alternative TR-FRET
approaches, e.g., the use of receptor constructs involving two dif-
ferent tags (Doumazane et al., 2010), are necessary to speciﬁcally
address this question.
CONCLUSION
In conclusion, this study (i) shows that preformed PRLR homod-
imers identiﬁed by co-IP can be detected using TR-FRET, (ii)
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demonstrates that receptor blockade does not involve disruption
of preformed PRLR dimers, (iii) suggests that receptor activa-
tion or blockade induce neither detectable change of receptor
stoichiometry nor signiﬁcant movement leading to a change in
the distance between the ECDs, and (iv) indicates that none of
the parameters investigated in this study allowed to discriminate
PRLRWT from PRLRI146L. This latter observation suggests that
the basal activity of PRLRI146L may involve subtle intramolecular
peculiarities that await the determination of its 3D structure to be
identiﬁed.
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